Sydes MR, Mason MD, Spears MR, et al. Adding abiraterone acetate plus prednisolone (AAP) or docetaxel for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Directly randomised data from STAMPEDE (NCT00268476). ESMO 2017, abstract LBA31_PR.,James ND, De Bono J, Spears MR, et al. Adding abiraterone for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Outcomes in non-metastatic (M0) patients from STAMPEDE (NCT00268476). ESMO 2017, abstract LBA34.
Hoe bewijs uit de dagelijkse praktijk RCT’s kan aanvullen
okt 2021 | Dermato-oncologie